Rheumatoid ArthritisPhase 2/3SELECTSUNRISENCT02720523
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
A Phase 2/3 study testing Upadacitinib in people with Rheumatoid Arthritis, run by AbbVie at 50 sites in Japan.
Trial summary
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Upadacitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 197 participants
- Where
- 50 sitesJapan
- Study dates
- 22 Mar 2016to 7 Jun 2022
- Phase
- Phase 2/3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of rheumatoid arthritis (RA) for >= 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA.
- Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy >= 3 months and on a stable dose for >= 4 weeks prior to the first dose of study drug.
- Subject has >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
- Subjects with prior exposure to at most one biological disease-modifying anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects) after the required washout period. Specifically, prior to enrollment:
- Subjects with limited exposure to bDMARD (< 3 months) OR
- Subjects who are responding to bDMARD therapy but had to discontinue due to intolerability (regardless of treatment duration).
Who cannot join
- Prior exposure to any Janus kinase (JAK) inhibitor
- Subjects who are considered inadequate responders (lack of efficacy) to bDMARD therapy, after minimum 3 months treatment, as determined by the Investigator.
- History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome is permitted.
Trial locations and contacts
50 sites in 1 country.
50 sites in 1 country
Japan50 sites
National Hospital Organization Asahikawa Medical Center /ID# 147994
Asahikawa, Hokkaido, 070-8644
Katayama Orthopedic Rheumatology Clinic /ID# 147976
Asahikawa, Hokkaido, 078-8243
NHO Chiba-East-Hospital /ID# 147996
Chiba, 260-8712
St.Luke's International Hospital /ID# 147969
Chuo-ku, Tokyo, 104-8560
Sugimoto Rheumatology and Internal Medicine Clinic /ID# 147989
Fukui, 910-0068
Hamanomachi Hospital /ID# 147991
Fukuoka, Fukuoka, 810-8539
Kyushu University Hospital /ID# 148008
Fukuoka, Fukuoka, 812-8582
Hopsital of the University of Occupational and Enviromental Health /ID# 147970
Fukuoka, 8078556
Shono Rheumatism Clinic /ID# 147971
Fukuoka, 814-0002
Hiroshima Rheumatology Clinic /ID# 147981
Hiroshima, 730-0017
Ichinomiya Municipal Hospital /ID# 147992
Ichinomiya-shi, Tokyo, 491-8558
Matsubara Mayflower Hospital /ID# 147967
Katō, 673-1462
Saitama Medical Center, Saitama Medical University /ID# 147965
Kawagoe-shi, Saitama, 350-8550
Kumamoto Orthopaedic Hospital /ID# 147972
Kumamoto, Kumamoto, 862-0976
Kumamoto Rheumatology Clinic /ID# 147988
Kumamoto, 861-5515
St. Mary's Hospital /ID# 147979
Kurume, 830-8543
Kagawa University Hospital /ID# 148001
Kyoto, 615-8256
Marunouchi Hospital /ID# 147973
Matsumoto, 390-0841
Toho University Ohashi Medical Center /ID# 148003
Meguro-ku, Tokyo, 1538515
Yu Family Clinic /ID# 147990
Miyagi, 981-0112
Medical Corporation Keiai Kai Clinic /ID# 147975
Miyazaki, Miyazaki, 880-0053
Nagaoka Red Cross Hospital /ID# 147974
Nagaoka-shi, Niigata, 940-2108
Nagoya University Hospital /ID# 148005
Nagoya, Aichi-ken, 466-8560
JP Red Cross Nagoya Daiichi /ID# 147995
Nagoya, 453-8511
Kondo Clinic for Ortho & Rheum /ID# 147984
Nagoya, 464-0071
The Hospital of Hyogo College of Medicine /ID# 147978
Nishinomiya-shi, Hyōgo, 663-8501
Oribe Clinic of Rheumatology and Internal Medicine /ID# 149308
Ōita, 870-0823
Okayama City Gen Med Ctr /ID# 148000
Okayama, 700-8557
Miyashita Rheumatology Clinic /ID# 147997
Ōmura, 856-0836
NHO Osaka Minami Med Ctr /ID# 147986
Osaka, Kawachinagano-shi, 586-8521
National Hospital Organization Sagamihara National Hospital /ID# 148221
Sagamihara-shi, Kanagawa, 252-0315
Sagawa Akira Rheumatology Clin /ID# 147987
Sapporo, 060-0001
Sapporo City General Hospital /ID# 147968
Sapporo, 060-8604
Tohoku University Hospital /ID# 148435
Sendai, Miyagi, 980-8574
Hikarigaoka Spellman Hospital /ID# 147993
Sendai, 983-0833
Setagaya Rheumatic Clinic /ID# 148009
Setagaya-ku, Tokyo, 156-0052
Niigata Rheumatic Center /ID# 148002
Shibata-shi, Niigata, 957-0054
Tokito Clinic Rheumatology and Orthopaedics Surgery /ID# 147980
Shimonoseki-shi, Yamaguchi, 752-0976
Jichi Medical University Hospital /ID# 148220
Shimotsuke-shi, Tochigi, 329-0498
Keio University Hospital /ID# 147982
Shinjuku-ku, Tokyo, 160-8582
Tokyo Women's Medical University Hospital /ID# 148007
Shinjuku-ku, Tokyo, 162-8666
Medical Corporation Uchida Clinic /ID# 148219
Sumida-ku, Tokyo, 130-0013
Honjo Rheumatism Clinic /ID# 147983
Takaoka, 933-0874
Inoue Hospital /ID# 147966
Takasaki, Gunma, 3700053
Takikawa Municipal Hospital /ID# 149309
Takikawa, 073-0022
Juntendo University Hospital /ID# 147999
Tokyo, 113-8431
National Hospital Organization Tokyo Medical Center /ID# 147998
Tokyo, 152-8902
Nihon University Itabashi Hosp /ID# 147977
Tokyo, 173-0032
Oki Medical Clinic /ID# 147985
Tomakomai, 053-0018
Toneyama National Hospital /ID# 148006
Toyonaka, 560-8552
About this study
Official title: A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response.
Following marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study will become a post-marketing clinical study and include a long-term extension period.
Read the detailed description
This study consisted of a 35-day screening period; a 12-week randomized, double-blind, parallel-group, placebo-controlled treatment period (Period 1); a 248-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).
Participants who met eligibility criteria were randomized in a 3:3:3:1:1:1 ratio to one of six treatment groups:
- Group 1: Upadacitinib 7.5 mg QD (Period 1) → upadacitinib 7.5 mg QD (Period 2)
- Group 2: Upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
- Group 3: Upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
- Group 4: Placebo (Period 1) → upadacitinib 7.5 mg QD (Period 2)
- Group 5: Placebo (Period 1) → upadacitinib 15 mg QD (Period 2)
- Group 6: Placebo (Period 1) → upadacitinib 30 mg QD (Period 2)
- Conditions
- Rheumatoid Arthritis
- Being tested
- Placebo, Upadacitinib
- Keywords
- rheumatoid arthritis, ABT-494, Japanese, Antirheumatic agents
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Tablet; Oral
UpadacitinibDrug
Also called ABT-494, RINVOQ™
Tablet; Oral
| Study group | Role | What they receive |
|---|---|---|
| Placebo / Upadacitinib 7.5 mg | Experimental | Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks. Receives: Drug: Placebo; Drug: Upadacitinib |
| Placebo / Upadacitinib 15 mg | Experimental | Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks. Receives: Drug: Placebo; Drug: Upadacitinib |
| Placebo / Upadacitinib 30 mg | Experimental | Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks. Receives: Drug: Placebo; Drug: Upadacitinib |
| Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Experimental | Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks. Receives: Drug: Upadacitinib |
| Upadacitinib 15 mg / Upadacitinib 15 mg | Experimental | Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks. Receives: Drug: Upadacitinib |
| Upadacitinib 30 mg / Upadacitinib 30 mg | Experimental | Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks. Receives: Drug: Upadacitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
- ≥ 20% improvement in 68-tender joint count;
- ≥ 20% improvement in 66-swollen joint count; and
- ≥ 20% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Health Assessment Questionnaire - Disability Index (HAQ-DI)
- High-sensitivity C-reactive protein (hsCRP).
Measured: Baseline and Week 12
Secondary outcomes (11)
Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
Measured: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.
Measured: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
- ≥ 50% improvement in 68-tender joint count;
- ≥ 50% improvement in 66-swollen joint count; and
- ≥ 50% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Health Assessment Questionnaire - Disability Index (HAQ-DI)
- High-sensitivity C-reactive protein (hsCRP).
Measured: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
- ≥ 70% improvement in 68-tender joint count;
- ≥ 70% improvement in 66-swollen joint count; and
- ≥ 70% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Health Assessment Questionnaire - Disability Index (HAQ-DI)
- High-sensitivity C-reactive protein (hsCRP).
Measured: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
Measured: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Low disease activity. was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
Measured: Week 12
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
Measured: Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
- ≥ 20% improvement in 68-tender joint count;
- ≥ 20% improvement in 66-swollen joint count; and
- ≥ 20% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Health Assessment Questionnaire - Disability Index (HAQ-DI)
- High-sensitivity C-reactive protein (hsCRP).
Measured: Baseline and Week 1
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12
The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.
Measured: Baseline and Week 12
Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12
RA-WIS is a simple validated tool to evaluate work instability (the consequence of a mismatch between an individual's functional ability and their work tasks). RA-WIS consists of 23 questions relating to the participant's functioning in their work environment, each answered as Yes or No. The total score is the number of questions answered Yes, and ranges from 0 to 23.
A score < 10 means low risk and no action is needed, scores between 10 and 17 indicate medium risk and appropriate advice and information should be given. If the score is > 17, it means high risk and it could warrant referral.
A negative change from Baseline indicates improvement.
Measured: Baseline and Week 12
Change From Baseline in the Severity of Morning Stiffness at Week 12
Morning stiffness severity was determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. Participants rated the severity of morning stiffness on awakening over the past 7 days on a scale from 0 (No morning stiffness) to 10 (Worst possible morning stiffness).
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2016 (estimated)
- Study start22 Mar 2016
- Primary completion3 Aug 2017
- Study completion7 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 197 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02720523
- Sponsor's protocol ID
- M14-663
- Acronym
- SELECTSUNRISE
- Status last verified
- Jun 2023
- First submitted
- 22 Mar 2016
- Last updated
- 7 Jun 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Publications
Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Kitamura S, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020 Nov 1;59(11):3303-3313. doi: 10.1093/rheumatology/keaa084.
PubMed 32277824Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Konishi Y, Chonan S, Ikeda K, Camp HS, Tanaka Y. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial. RMD Open. 2025 Nov 4;11(4):e006213. doi: 10.1136/rmdopen-2025-006213.
PubMed 41193232Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.
PubMed 34041702Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021 Jan 6;23(1):9. doi: 10.1186/s13075-020-02387-6.
PubMed 33407801
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
- ClinicalTrials.gov ID
- NCT02720523
- Acronym / sponsor ID
- SELECTSUNRISE / M14-663
- Conditions
- Rheumatoid Arthritis
- Keywords
- rheumatoid arthritis, ABT-494, Japanese, Antirheumatic agents
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 197 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 22 Mar 2016 (actual)
- Primary completion
- 3 Aug 2017 (actual)
- Study completion
- 7 Jun 2022 (actual)
- First posted
- 28 Mar 2016 (estimated)
- Results
- Posted 21 Oct 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response.
Following marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study will become a post-marketing clinical study and include a long-term extension period.
Detailed description
This study consisted of a 35-day screening period; a 12-week randomized, double-blind, parallel-group, placebo-controlled treatment period (Period 1); a 248-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).
Participants who met eligibility criteria were randomized in a 3:3:3:1:1:1 ratio to one of six treatment groups:
- Group 1: Upadacitinib 7.5 mg QD (Period 1) → upadacitinib 7.5 mg QD (Period 2)
- Group 2: Upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
- Group 3: Upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
- Group 4: Placebo (Period 1) → upadacitinib 7.5 mg QD (Period 2)
- Group 5: Placebo (Period 1) → upadacitinib 15 mg QD (Period 2)
- Group 6: Placebo (Period 1) → upadacitinib 30 mg QD (Period 2)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Placebo / Upadacitinib 7.5 mg | Experimental | Drug: Placebo, Drug: UpadacitinibPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks. |
| Placebo / Upadacitinib 15 mg | Experimental | Drug: Placebo, Drug: UpadacitinibPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks. |
| Placebo / Upadacitinib 30 mg | Experimental | Drug: Placebo, Drug: UpadacitinibPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks. |
| Upadacitinib 7.5 mg / Upadacitinib 7.5 mg | Experimental | Drug: UpadacitinibPeriod 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks. |
| Upadacitinib 15 mg / Upadacitinib 15 mg | Experimental | Drug: UpadacitinibPeriod 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks. |
| Upadacitinib 30 mg / Upadacitinib 30 mg | Experimental | Drug: UpadacitinibPeriod 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosis of rheumatoid arthritis (RA) for >= 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA.
- Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy >= 3 months and on a stable dose for >= 4 weeks prior to the first dose of study drug.
- Subject has >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
- Subjects with prior exposure to at most one biological disease-modifying anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects) after the required washout period. Specifically, prior to enrollment:
Key exclusion criteria (3 listed)
- Prior exposure to any Janus kinase (JAK) inhibitor
- Subjects who are considered inadequate responders (lack of efficacy) to bDMARD therapy, after minimum 3 months treatment, as determined by the Investigator.
- History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome is permitted.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboTablet; Oral | Drug | Placebo / Upadacitinib 15 mg, Placebo / Upadacitinib 30 mg, Placebo / Upadacitinib 7.5 mg |
| UpadacitinibAlso: ABT-494, RINVOQ™Tablet; Oral | Drug | Placebo / Upadacitinib 15 mg, Placebo / Upadacitinib 30 mg, Placebo / Upadacitinib 7.5 mg, Upadacitinib 15 mg / Upadacitinib 15 mg, Upadacitinib 30 mg / Upadacitinib 30 mg, Upadacitinib 7.5 mg / Upadacitinib 7.5 mg |
Primary outcome
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Time frame: Baseline and Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
11 secondary outcomes
Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Time frame: Week 12
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
Time frame: Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Time frame: Baseline and Week 1
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in the Severity of Morning Stiffness at Week 12
Time frame: Baseline and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 32277824Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Kitamura S, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020 Nov 1;59(11):3303-3313. doi: 10.1093/rheumatology/keaa084.
- Derived from this study: PubMed 41193232Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Konishi Y, Chonan S, Ikeda K, Camp HS, Tanaka Y. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial. RMD Open. 2025 Nov 4;11(4):e006213. doi: 10.1136/rmdopen-2025-006213.
- Derived from this study: PubMed 34041702Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.
- Derived from this study: PubMed 33407801Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021 Jan 6;23(1):9. doi: 10.1186/s13075-020-02387-6.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
50 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Upadacitinib in people with Rheumatoid Arthritis, run by AbbVie at 50 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 50 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Oct 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02720523, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2023.